D-Allulose Attenuates High-Fat Diet-Induced NAFLD in Mice by Reducing Lipid Accumulation and Inflammation

A Sugar Substitute That Targets the Liver

If you formulate for metabolic health, allulose keeps showing up in the evidence. The latest animal study gives it a new layer of relevance: liver protection. In mice with high-fat diet-induced NAFLD, D-allulose reduced liver fat and inflammation. That is a meaningful finding for food formulators because NAFLD is no longer just a clinical issue. It is a reformulation target.

Background: Why Allulose Is Different

Allulose, also known as D-psicose, is a rare sugar with a real sweetness profile. But its metabolic behavior is nothing like sucrose. D-allulose provides only 0.3% of sucrose’s energy. That alone makes it attractive for sugar reduction. The study adds more. It shows D-allulose has anti-inflammatory properties and can inhibit lipid synthesis. In other words, it may do more than replace sweetness. It may actively support liver health in the right context.

What the Study Did

Published in Frontiers in Nutrition with DOI 10.3389/fnut.2025.1574151, the research team used a high-fat diet to induce NAFLD in mice. Then they gave D-allulose and looked at what changed. The team measured liver lipid accumulation, inflammatory injury, blood lipids, oxidative stress, gut microbiota composition, and serum metabolome balance. That is a wide net. The results point to a consistent protective effect.

Key Findings

D-allulose significantly reduced hepatic lipid accumulation in the NAFLD mice. Inflammatory injury also dropped. Blood lipid profiles improved, and oxidative stress status got better. The microbiota shifted too. Beneficial bacteria, including Akkermansia, increased in abundance. Serum metabolome balance was restored.

Here is a quick comparison of what the study reported for D-allulose versus sucrose:

Attribute	D-Allulose	Sucrose
Energy relative to sucrose	0.3%	Reference (100%)
Lipid synthesis in NAFLD mice	Inhibited	No data in this paper
Liver lipid accumulation	Reduced	No data in this paper
Inflammatory injury	Reduced	No data in this paper
Gut Akkermansia abundance	Increased	No data in this paper

That table does not mean allulose is a drug. It means the biological activity is real enough to study further.

What This Means for Manufacturers

For ingredient buyers, the immediate takeaway is simple. Allulose can be positioned as more than a low-calorie sweetener. It brings a functional story around lipid metabolism, inflammation, and gut health. That story matters for products aimed at weight management, blood sugar control, and liver wellness.

The 0.3% energy figure is a powerful label message. Replacing sucrose with allulose cuts calories while keeping sweetness. But the liver data adds another layer. If you sell into the metabolic health space, this study gives you a reason to discuss allulose as an active ingredient, not just a sugar stand-in.

Still, keep perspective. This is a mouse study. Disease-related claims are not allowed on food labels. But internal formulation decisions and B2B marketing can use this evidence to guide product development.

FAQ

Is D-allulose the same as D-psicose?
Yes. The paper uses DPS as shorthand. D-psicose is another name for allulose.

Did the study use allulose in a real food product?
No. The mice received D-allulose in the context of a high-fat diet model. It was not a finished food application. The evidence supports mechanism, not a specific product claim.

Can I claim NAFLD benefits on a label?
No. This is preclinical animal data. You can talk about allulose as a low-calorie sugar, but disease-related language would create regulatory risk.

Allulose keeps earning attention for reasons beyond sweetness. This study adds liver protection to that list. Watch for human trials. If they confirm what this mouse model shows, allulose becomes a more valuable tool in metabolic health formulation.